Retinoblastoma

Clinical Research Studies

Physicians and researchers from the Retinoblastoma Program within the Cancer & Blood Diseases Institute at Cincinnati Children's Hospital Medical Center offer clinical research studies for children with retinoblastoma.

• ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
• NCI-07-C-0040: A Phase I Trial of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors
• ADVL0413: Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias
• ADVL0812: A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Pediatric Patients With Relapsed/Refractory Solid Tumors and Leukemia
• ADVL0714: A Phase I Study of VEGF Trap in Children with Refractory Solid Tumors
• VITAC: A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan and Temozolomide (VOIT regiment) for Relapsed/Refractory Pediatric Solid Tumors

Find a Service Alphabetically

Cancer & Blood Diseases Institute

• What Sets Us Apart
• Cancer
  • Diagnosis & Treatment
  • Cancer Survivor Center
  • Brain & Spinal Tumors
  • Hemangioma & Vascular Malformation
  • Kidney Tumors
  • Leukemia & Lymphoma
  • Liver Tumors
  • Musculoskeletal Tumors
  • Neuroblastoma
  • Neurofibromatosis Tumors
  • Retinoblastoma
    • Comprehensive Care
    • Mutidisciplinary Care
    • Meet Our Team
    • Therapies
    • Research
    • Clinical Trials
    • Contact Us
    • Related Resources
  • Pain Management
  • State-of-the-Art Facilities
  • Fighting Cancer in the Lab
• Blood Diseases
• Bone Marrow Transplantation
• Immune Deficiency & Histiocytosis
• Patient & Family Resources
• Health Professional Resources
• Make a Gift